Paper Details

  1. Home
  2. Paper Details

Pimavanserin use in a movement disorders clinic: a single-center experience.

Author: AhmadAyesha, BulicaBisena, KaminskiPatricia, KrstevskaShana, LeWittPeter, MahajanAbhimanyu, PatelNeepa, TaylorDanette

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Parkinson's disease psychosis (PDP) is a challenging symptom of Parkinson's disease (PD) to treat. While dopamine receptor blockers (DRB) are used, they can worsen Parkinsonism. Pimavanserin, a 5-HT<sub>2A</sub> receptor inverse agonist, has been approved for PDP treatment, but long-term data are limited.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND" NlmCategory="BACKGROUND">Parkinson's disease psychosis (PDP) is a disabling non-motor symptom of Parkinson's disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10072-018-3500-5

データ提供：米国国立医学図書館（NLM）

Navigating Parkinson's Disease Psychosis: Exploring Pimavanserin's Role

Parkinson's disease psychosis (PDP) is a debilitating complication of Parkinson's disease (PD) that poses significant challenges for treatment. This research explores the use of pimavanserin, a selective 5-HT2A receptor inverse agonist, for managing PDP. While pimavanserin is FDA-approved for PDP, its long-term use in this patient population is not well-established.

Pimavanserin: A Potential Pathway for Managing PDP

The study provides insights into the clinical experience with pimavanserin in a movement disorders clinic, offering valuable data on its potential efficacy and safety in the long-term management of PDP. This research contributes to the understanding of pimavanserin's role in treating PDP, particularly in the context of its potential benefits and risks.

Navigating the Shifting Sands of Parkinson's Disease: Seeking Effective Treatments

Parkinson's disease, like a shifting desert landscape, presents unique challenges for patients and their healthcare providers. This study highlights the importance of exploring new treatment options, such as pimavanserin, to effectively manage PDP and improve quality of life for individuals living with PD.

Dr.Camel's Conclusion

The desert of Parkinson's disease can be unforgiving, but pimavanserin emerges as a potential oasis for individuals struggling with PDP. This study offers valuable insights into its potential as a treatment option, emphasizing the ongoing need for research to further explore its efficacy and safety in the long term.

Date :
  1. Date Completed 2018-11-05
  2. Date Revised 2018-11-14
Further Info :

Pubmed ID

30032332

DOI: Digital Object Identifier

10.1007/s10072-018-3500-5

Related Literature

Article Analysis
・Side Effects of pimavanserin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.